Literature DB >> 31119317

FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis.

Frederik L Giesel1, Claus Peter Heussel2,3,4, Thomas Lindner1, Manuel Röhrich1, Hendrik Rathke1, Hans-Ulrich Kauczor3,4, Jürgen Debus5, Uwe Haberkorn1,3,6, Clemens Kratochwil7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31119317     DOI： 10.1007/s00259-019-04346-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.

Authors:  Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

2.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 3.  PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies.

Authors:  Paul Flechsig; Amit Mehndiratta; Uwe Haberkorn; Clemens Kratochwil; Frederik L Giesel
Journal:  Semin Nucl Med       Date:  2015-07       Impact factor: 4.446

4.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.

Authors:  Anastasia Loktev; Thomas Lindner; Walter Mier; Jürgen Debus; Annette Altmann; Dirk Jäger; Frederik Giesel; Clemens Kratochwil; Philippe Barthe; Christian Roumestand; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

5.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.

Authors:  Frederik L Giesel; Clemens Kratochwil; Thomas Lindner; Manfred M Marschalek; Anastasia Loktev; Wencke Lehnert; Jürgen Debus; Dirk Jäger; Paul Flechsig; Annette Altmann; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-08-02       Impact factor: 10.057
  5 in total
  13 in total

1.  Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.

Authors:  Thomas Lindner; Annette Altmann; Susanne Krämer; Christian Kleist; Anastasia Loktev; Clemens Kratochwil; Frederik Giesel; Walter Mier; Frederik Marme; Jürgen Debus; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

2.  Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC.

Authors:  Xin Zhou; Shuailiang Wang; Xiaoxia Xu; Xiangxi Meng; Huiyuan Zhang; Annan Zhang; Yufei Song; Hua Zhu; Zhi Yang; Nan Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-11       Impact factor: 10.057

Review 3.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

4.  Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.

Authors:  Euy Sung Moon; Filipe Elvas; Gwendolyn Vliegen; Stef De Lombaerde; Christel Vangestel; Sven De Bruycker; An Bracke; Elisabeth Eppard; Lukas Greifenstein; Benedikt Klasen; Vasko Kramer; Steven Staelens; Ingrid De Meester; Pieter Van der Veken; Frank Rösch
Journal:  EJNMMI Radiopharm Chem       Date:  2020-07-29

Review 5.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

Review 6.  Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors:  Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  EJNMMI Res       Date:  2021-02-19       Impact factor: 3.138

7.  A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging.

Authors:  Barbara Katharina Geist; Haiqun Xing; Jingnan Wang; Ximin Shi; Haitao Zhao; Marcus Hacker; Xinting Sang; Li Huo; Xiang Li
Journal:  EJNMMI Phys       Date:  2021-01-22

8.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.

Authors:  Catherine Meyer; Magnus Dahlbom; Thomas Lindner; Sebastien Vauclin; Christine Mona; Roger Slavik; Johannes Czernin; Uwe Haberkorn; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

Review 9.  Targeting of activated fibroblasts for imaging and therapy.

Authors:  Thomas Lindner; Anastasia Loktev; Frederik Giesel; Clemens Kratochwil; Annette Altmann; Uwe Haberkorn
Journal:  EJNMMI Radiopharm Chem       Date:  2019-07-25

10.  FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients.

Authors:  Frederik L Giesel; Sebastian Adeberg; Mustafa Syed; Thomas Lindner; Luis David Jiménez-Franco; Eleni Mavriopoulou; Fabian Staudinger; Eric Tonndorf-Martini; Sebastian Regnery; Stefan Rieken; Rami El Shafie; Manuel Röhrich; Paul Flechsig; Andreas Kluge; Annette Altmann; Jürgen Debus; Uwe Haberkorn; Clemens Kratochwil
Journal:  J Nucl Med       Date:  2020-06-26       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.